Skip to Content
Merck
CN

H146

4-Hydroxymephenytoin

≥98% (HPLC)

Synonym(s):

(±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylhydantoin, (±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylimididazolidine-2,4-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C12H14N2O3
CAS Number:
61837-65-8
Molecular Weight:
234.25
NACRES:
NA.22
PubChem Substance ID:
57654234
UNSPSC Code:
12352100
MDL number:
MFCD00142316
Assay:
≥98% (HPLC)

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)

SMILES string

CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2

InChI key

OQPLORUDZLXXPD-UHFFFAOYSA-N

assay

≥98% (HPLC)

solubility

DMSO: >5 mg/mL

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

CYP2C19 metabolite of mephenytoin.

Application

Pharmacological activity investigating:
  • The drug effects on metabolization
  • In vitro cytochrome P450 activity in microsomes

Analyte for electron-capture gas chromatography procedures

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000439380
0000439380
0000199199
0000155063
0000150354

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
C Desiderio et al.
Electrophoresis, 15(1), 87-93 (1994-01-01)
Using cyclodextrin micellar electrokinetic capillary chromatography (CD-MECC), baseline separation of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in urine was effected with beta-cyclodextrin. After single-dose administration of 100 mg of racemic mephenytoin, the 0-8 h urine was collected, and enzymatically hydrolyzed urine
A Adedoyin et al.
Clinical pharmacology and therapeutics, 64(1), 8-17 (1998-08-08)
Drug metabolism is influenced by liver disease because of the central role that the liver plays in metabolic activities in the body. However, it is still unclear how activities of specific drug-metabolizing enzymes are influenced by the presence and severity
Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
M Bajpai et al.
Drug metabolism and disposition: the biological fate of chemicals, 24(12), 1401-1403 (1996-12-01)
H J Feng et al.
British journal of clinical pharmacology, 45(1), 27-29 (1998-03-07)
To determine the induction effect of rifampicin on the activity of 4'-hydroxylase in poor metabolizers (PMs) with m1 mutation of S-mephenytoin 4'-hydroxylation and the relationship of the effect with gene dose. Seven extensive metabolizers (EMs) of S-mephenytoin 4'-hydroxylation and five
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service